Online inquiry

IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ11255MR)

This product GTTS-WQ11255MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & Pseudo-UTP. It ecodes the monoclonal antibody that targets CD274 gene. The antibody can be applied in Solid tumors, Small Cell Lung Cancer (SCLC) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq NM_001267706.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 29126
UniProt ID Q9NZQ7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-CD274, MEDI4736(Cap 0, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ11255MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ15007MR IVTScrip™ mRNA-Anti-CD19, SJ25C1 scFv-28Z CAR(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA SJ25C1 scFv-28Z CAR
GTTS-WQ14899MR IVTScrip™ mRNA-Anti-stx1B, Shigamabs®(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3516MR IVTScrip™ mRNA-Anti-APP, BART(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA BART
GTTS-WQ4486MR IVTScrip™ mRNA-Anti-CD28, BMS-931699(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA BMS-931699
GTTS-WQ12651MR IVTScrip™ mRNA-Anti-RSPO3, OMP-131R10(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA OMP-131R10
GTTS-WQ13295MR IVTScrip™ mRNA-Anti-PTK7, PF-06523435(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA PF-06523435
GTTS-WQ5126MR IVTScrip™ mRNA-Anti-IL1RAP, CAN-04(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CAN-04
GTTS-WQ12598MR IVTScrip™ mRNA-Anti-F11, NVS250519(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA NVS250519
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW